Cognition Therapeutics (CGTX) Competitors $0.46 -0.05 (-9.78%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CGTX vs. BOLT, INKT, AVTX, DARE, ELEV, ORMP, CHRS, CDTX, HOWL, and OPTNShould you be buying Cognition Therapeutics stock or one of its competitors? The main competitors of Cognition Therapeutics include Bolt Biotherapeutics (BOLT), MiNK Therapeutics (INKT), Avalo Therapeutics (AVTX), Daré Bioscience (DARE), Elevation Oncology (ELEV), Oramed Pharmaceuticals (ORMP), Coherus BioSciences (CHRS), Cidara Therapeutics (CDTX), Werewolf Therapeutics (HOWL), and OptiNose (OPTN). These companies are all part of the "medical" sector. Cognition Therapeutics vs. Bolt Biotherapeutics MiNK Therapeutics Avalo Therapeutics Daré Bioscience Elevation Oncology Oramed Pharmaceuticals Coherus BioSciences Cidara Therapeutics Werewolf Therapeutics OptiNose Cognition Therapeutics (NASDAQ:CGTX) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation, analyst recommendations and community ranking. Which has more risk & volatility, CGTX or BOLT? Cognition Therapeutics has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Do analysts recommend CGTX or BOLT? Cognition Therapeutics presently has a consensus price target of $8.00, suggesting a potential upside of 1,634.61%. Bolt Biotherapeutics has a consensus price target of $3.50, suggesting a potential upside of 518.92%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cognition Therapeutics is more favorable than Bolt Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cognition Therapeutics 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67Bolt Biotherapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher valuation and earnings, CGTX or BOLT? Cognition Therapeutics has higher earnings, but lower revenue than Bolt Biotherapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCognition TherapeuticsN/AN/A-$25.79M-$0.97-0.48Bolt Biotherapeutics$7.88M2.75-$69.20M-$1.71-0.33 Does the media favor CGTX or BOLT? In the previous week, Bolt Biotherapeutics had 4 more articles in the media than Cognition Therapeutics. MarketBeat recorded 13 mentions for Bolt Biotherapeutics and 9 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.21 beat Bolt Biotherapeutics' score of -0.09 indicating that Cognition Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bolt Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in CGTX or BOLT? 43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 20.8% of Cognition Therapeutics shares are held by insiders. Comparatively, 30.9% of Bolt Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in CGTX or BOLT? Bolt Biotherapeutics received 64 more outperform votes than Cognition Therapeutics when rated by MarketBeat users. Likewise, 64.52% of users gave Bolt Biotherapeutics an outperform vote while only 64.00% of users gave Cognition Therapeutics an outperform vote. CompanyUnderperformOutperformCognition TherapeuticsOutperform Votes1664.00% Underperform Votes936.00% Bolt BiotherapeuticsOutperform Votes8064.52% Underperform Votes4435.48% Is CGTX or BOLT more profitable? Cognition Therapeutics has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -665.56%. Bolt Biotherapeutics' return on equity of -69.46% beat Cognition Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cognition TherapeuticsN/A -150.93% -100.82% Bolt Biotherapeutics -665.56%-69.46%-48.55% SummaryBolt Biotherapeutics beats Cognition Therapeutics on 9 of the 17 factors compared between the two stocks. Ad Genesis Gold GroupTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGTX vs. The Competition Export to ExcelMetricCognition TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.16M$2.93B$5.15B$8.74BDividend YieldN/A1.88%5.18%4.08%P/E Ratio-0.4816.5966.6713.57Price / SalesN/A284.431,276.8487.67Price / CashN/A166.9239.7035.24Price / Book1.324.006.475.93Net Income-$25.79M-$42.42M$119.73M$225.73M7 Day Performance-8.67%-10.63%-5.13%-1.34%1 Month Performance3.50%-5.81%-2.71%1.15%1 Year Performance-55.22%24.19%31.08%24.02% Cognition Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGTXCognition Therapeutics2.8666 of 5 stars$0.46-9.8%$8.00+1,634.6%-53.9%$19.16MN/A-0.4820Analyst ForecastShort Interest ↑News CoverageGap DownBOLTBolt Biotherapeutics3.5049 of 5 stars$0.64+1.6%N/A-40.5%$24.56M$7.88M-0.37100Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageINKTMiNK Therapeutics2.907 of 5 stars$0.78+4.0%N/A-23.6%$30.84MN/A-1.5930Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageGap UpAVTXAvalo Therapeutics2.6152 of 5 stars$12.81-3.3%N/A-43.8%$13.25M$807,000.000.0040Short Interest ↓DAREDaré Bioscience2.1054 of 5 stars$4.41+0.2%N/A-20.1%$37.71M$2.81M-3.9330Analyst ForecastShort Interest ↓News CoverageELEVElevation Oncology1.935 of 5 stars$0.69+3.0%N/A+11.6%$40.75MN/A-0.8440Gap UpORMPOramed Pharmaceuticals2 of 5 stars$2.34+0.9%N/A+9.3%$95.40M$1.34M4.5910Positive NewsCHRSCoherus BioSciences3.7156 of 5 stars$0.82+5.1%N/A-56.5%$94.88M$304.34M-10.29246Short Interest ↑Gap UpCDTXCidara Therapeutics4.3897 of 5 stars$13.45+0.7%N/A-10.5%$94.69M$63.90M-0.5390Analyst RevisionNews CoverageHOWLWerewolf Therapeutics3.6312 of 5 stars$2.15-2.3%N/A-21.0%$93.96M$9.28M-1.4140Short Interest ↑Analyst RevisionPositive NewsOPTNOptiNose3.9652 of 5 stars$0.60-22.1%N/A-65.2%$90.47M$70.99M-1.67190Analyst ForecastAnalyst RevisionNews CoverageHigh Trading Volume Related Companies and Tools Related Companies Bolt Biotherapeutics Competitors MiNK Therapeutics Competitors Avalo Therapeutics Competitors Daré Bioscience Competitors Elevation Oncology Competitors Oramed Pharmaceuticals Competitors Coherus BioSciences Competitors Cidara Therapeutics Competitors Werewolf Therapeutics Competitors OptiNose Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CGTX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CGTX Stock Alerts